Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults [1]

New England Journal of Medicine

Volumn 362, Issue 21, 2010, Pages 2030-2031

  Lippi, Giuseppe ^a   Mattiuzzi, Camilla ^b   Targher, Giovanni ^b  

^a ACADEMIC HOSPITAL OF PARMA   (Italy)

^b General Direction   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; GLYCOSYLATION; HUMAN; IRON DEFICIENCY ANEMIA; LETTER; PRIORITY JOURNAL; BLOOD ANALYSIS; CALIBRATION; CARDIOVASCULAR DISEASE; METABOLISM; NOTE; RISK; STANDARD;

BLOOD CHEMICAL ANALYSIS; CALIBRATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RISK;

EID: 77952772989     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1003829     Document Type: Letter

References (4)

1. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811
2. Kramer CK, Araneta MR, Barrett-Connor E. A1C and diabetes diagnosis: the Rancho Bernardo Study. Diabetes Care 2010;33:101-103
3. Sacks DB. The diagnosis of diabetes is changing: how implementation of hemoglobin A1c will impact clinical laboratories. Clin Chem 2009;55:1612-1614
4. Bloomgarden ZT. A1C: recommendations, debates, and questions. Diabetes Care 2009;32(12):e141-e147.